, a CMO for the development and production of biopharmaceuticals, reported the investment of €24 million (approximately $32 million) to build a twin system with two 3000-L stainless-steel bioreactors mainly targeting market supply at the company’s site in Laupheim, Germany. The twin system should be operational in early 2017.

The twin system is designed for running two main bioreactors in parallel with one shared downstream processing unit, thus providing higher throughput while reducing incremental labor costs involved. It will be integrated into the existing 3000-L GMP line and will more than double the production capacities for cell culture-derived proteins. The twin system will allow Rentschler to run cell-culture processes in fed-batch mode with a high output in a single suite.

Industry News

PharmTech News

Supplier News

PTSM: Pharmaceutical Technology Sourcing and Management-07-02-2014

Rentschler plans to build two stainless-steel bioreactors to target market supply.